Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solanezumab Biomarker Study in Alzheimer's and Controls
NCT01148498Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2010
- Primary completion
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of solanezumab in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in plasma levels of Aβ fragment-2 at 112 days. Started Aug 2010; status: completed.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01148498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01148498.